kyvernatx.com - שווי מצרפי של הפעילות העסקית KYTX

Kyverna Therapeutics (KYTX) is developing unique CAR-T solutions to combat severe systemic pathologies, avoiding price competition due to a lack of direct analogs. Business revenues will be based on the market launch of personalized T-cell products targeting sclerosis and lupus. This price chart, showing an enterprise value of 195.36, complements data regarding California laboratories and a network of manufacturing partners.
Kyverna Therapeutics (KYTX) - פילוחי מדדים ודוחות פיננסיים

Inelastic demand for a unique CAR-T lupus therapy provides Kyverna Therapeutics (KYTX) with significant pricing power, which directly impacts the EV trend. This indicator aggregates market capitalization and debt, minus cash, to determine the actual cost of a full business buyout, allowing investors to assess the real scale of the enterprise without liquidity distortions.